Drug intelligence / Profile preview

OL-JC2

Development stage: Preclinical
Lead developer: Oleolive
Modality: Small Molecules
Administration: Inhalation

Overview

OL-JC2 is a preclinical-stage small molecule agonist of Casein Kinase 1 alpha (CK1α) being developed by Oleolive for the treatment of pulmonary fibrosis, specifically idiopathic pulmonary fibrosis (IPF). The compound is designed to block TGFβ-driven fibrotic pathways locally in the lung. To address challenges with oral bioavailability and minimize systemic side effects, Oleolive is developing OL-JC2 as an inhalable therapeutic. The drug was discovered through a high-content imaging screen aimed at identifying compounds that could inhibit TGFβ activity, a central driver of fibrosis. The development has been supported by grant funding from the National Heart, Lung, and Blood Institute (NHLBI).

Targets

CK1α (Casein kinase I alpha)

Beyond the preview

Go deeper on OL-JC2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OL-JC2.

Explore the full profile